Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Altay Therapeutics Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This specific matter is assigned to 1 distinct examiner, which creates a highly concentrated prosecution environment. The action is being reviewed within 1 distinct art unit, suggesting that the current focus of the company's patent efforts is limited to a specific technical niche within the broader biotechnology sector.
The examiner responsible for this action is CORNET, JEAN P, who holds 1 pending office action for the portfolio. Because this is the only pending matter, the company's immediate success at the patent office depends entirely on the interaction with this individual. Practitioners should focus on the specific examination history and preferences of CORNET, JEAN P to navigate the requirements of the assigned art unit effectively.
The presence of the current workload allows for a dedicated and tailored legal strategy. There is no need to coordinate across different examiners or manage conflicting requirements from various art units. The legal team can focus resources on the technical arguments relevant to the Biotechnology & Pharmaceuticals field as they pertain to this application and the standards of the assigned examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CORNET, JEAN P | 1 | 41.9% | +47.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19537121 | N-PHENYL-3-(2,5-DIOXOPYRROLIDIN-1-YL)PROPANAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS DUX4 INHIBITORS FOR THE TREATMENT OF E.G. NEUROMUSCULAR DISORDERS | CORNET, JEAN P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19537121 | N-PHENYL-3-(2,5-DIOXOPYRROLIDIN-1-YL)PROPANAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS DUX4 INHIBITORS FOR THE TREATMENT OF E.G. NEUROMUSCULAR DISORDERS | CORNET, JEAN P | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19537121 | N-PHENYL-3-(2,5-DIOXOPYRROLIDIN-1-YL)PROPANAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS DUX4 INHIBITORS FOR THE TREATMENT OF E.G. NEUROMUSCULAR DISORDERS | CORNET, JEAN P | 1628 | §102§103§112 | Final Rejection | — | Pending | Feb 11, 2026 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAltay Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jean P Cornet has the most, with 1 of Altay Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
